Sida laga soo xigtay natiijooyinka tijaabo caafimaad oo badan oo badan oo ay hogaaminayaan saynisyahano jooga Xarunta Cilmi-baarista Kansarka ee Dana Faber, ka dib markii daawaynta caadiga ah ay fashilanto, daawaynta daweynta ee la beegsaday ayaa yarayn karta xaddiga dhiigga ku qulqulaya burada, taas oo sii dheeraynaysa wakhtiga badbaadada bukaanada leh horumarsan. kansarka caloosha.
Tijaabo caafimaad oo la kala soocay, oo la xakameeyey wejiga III ee lagu daabacay The Lancet, cilmi-baarayaashu waxay soo sheegeen in bukaannada helay dawada antibody-ka ramucirumab ay la kulmeen dib u dhac dheer ka hor inta uusan kansarku horumarin marka la barbar dhigo bukaannada kooxda placebo.
Sababtoo ah saameynta xulashada ee antibody-kan, bukaanada qaata ramucirumab waxay inta badan leeyihiin saameyno dhexdhexaad ah, inkastoo bukaannadani ay leeyihiin wax yar oo kor u kaca heerka dhiig-karka marka loo eego bukaanka kooxda kantaroolka.
Dana Fabre oo ah cilmi-baadhaha kansarka iyo qoraaga koowaad ee REGARD warbixinta tijaabada bukaan-socodka Charles Fuchs, MD .; Master of Public Health ayaa yidhi: "Aad ayay u cajab galisay in antibody-kan uu leeyahay waxyeelooyin aad u yar, laakiin waxa ay bixin kartaa Faa'iido cad oo laga helo badbaadada. ”
Tijaabada caafimaadku waxa ay diiwaangelisay 355 bukaan oo qaba kansarka caloosha ama kansarka isgoysyada caloosha. Bukaanadan ayaa lagu daweeyay 119 xarumood oo caafimaad oo ku kala yaal 29 wadan.
Adduunka oo dhan, kansarka caloosha ayaa kaalinta labaad kaga jira dhimashada kansarka la xidhiidha, laakiin culayska kansarka caloosha ee Maraykanka ayaa aad u yar. Sannadkii 2013, waxa la soo sheegay 21,600 xaaladood oo cusub iyo 10.990 dhimasho ah. Daawaynta caadiga ah ee kansarka caloosha ee horumarsan waa kiimoterabi, laakiin haddii kansarku sii socdo, hadda ma jiro daawaynta safka labaad ee la oggolaaday.
"Waxaan ogaanay inaan u baahanahay daaweyn wanaagsan oo loogu talagalay kansarka caloosha, sababtoo ah inta badan, qaabka hadda jira ee isticmaalka daaweynta kemotherabi waa mid aad uga fog," ayuu yiri Fuchs, oo ah agaasimaha Waaxda Oncology Gastrointestinal Oncology ee Xarunta Kansarka Dana-Farber. "Waxaan u baahanahay inaan horumarino dawooyinka daweynta ee bartilmaameedka ah si loo daweeyo cudurkan, taas oo nooga baahan inaan si dhab ah u fahanno oo aan fiiro gaar ah u yeelano habka bayoolojiga ee cudurka."
Halkii laga rabi lahaa dawooyinka kiimikada sunta ah ee sunta ah si ay u dilaan ama uga hortagaan unugyada kansarka inay kala qaybiyaan, ramucirumab waxay beegsataa calaamadaha borotiinka ee wareegga taasoo kicisa samaynta xididdada dhiigga cusub si ay u taageerto koritaanka iyo faafidda burada. Ramucirumab waxaa loogu talagalay in lagu yareeyo samaynta xididdada dhiigga cusub (angiogenesis) iyada oo la xannibayo marinka calaamadaynta VEGF reseptor-2 (VEGFR-2), si aanay buradu u helin nafaqo iyo gaajo dhimasho. Ka-hortagga VEGFR-2 ee moodooyinka xayawaanka waxay hoos u dhigi kartaa koritaanka kansarka caloosha ee jiirarka.
Tijaabada bukaan-socodka ee ramucirumab, 355 bukaan oo qaba kansarka caloosha oo sareeyo waxay heleen dawooyinka ka hortagga jirka iyo daawaynta taageerada ugu fican labadii toddobaadba mar, halka 117 bukaan oo kale ay heleen placebo oo lagu daray daawaynta taageerada ugu fican.
Daraasada ayaa la soo gabagabeeyey bishii Luulyo 2012, waxaana falanqaynta muujisay in isticmaalka ramucirumab uu si weyn hoos ugu dhigi karo heerka dhimashada 22%. Intaa waxaa dheer, dhexdhexaadinta guud ee wakhtiga badbaadada bukaanada lagu daaweeyay gacanta ramucirumab waxay ahayd 5.2 bilood, marka la barbar dhigo 3.8 bilood kooxda placebo. Daawadu waxay dib u dhigtay horumarka kansarka 53%. Bukaannada qaata ramucirumab, heerka horumarka kansarka ee toddobaadyada 12 wuxuu ahaa 40%, marka la barbar dhigo 16% kooxda placebo. Cilmi-baadhayaashu waxay tixgeliyeen in ramucirumab, kansarka caloosha lagu xakameeyay wakhti dhexdhexaad ah oo ah 4.2 bilood, marka la barbar dhigo 2.9 bilood oo keliya kooxda placebo.
"Natiijadayadu waxay tahay in bukaannada qaata daawaynta antibody-ka ay si weyn u kordhin karaan waqtigooda badbaadada iyagoo si weyn u yareynaya heerka horumarka kansarka," Fuchs ayaa sidaas yidhi. "Natiijadu waa mid dhiirri-gelin leh, waxaana rajeyneynaa in dawadan ugu dambeyntii la oggolaado oo loo isticmaalo daawaynta caadiga ah ee bukaannada qaba kansarka caloosha." Waxa uu intaa ku daray in tijaabooyinka caafimaad ay socdaan si loo ogaado in ramucirumab lagu dari karo isku darka daaweynta kemotherabi Isticmaal "natiijooyinka bogsashada wanaagsan."
Dhibaatooyinka soo raaca ayaa ah kuwo caan ku ah labada kooxoodba, iyo dhacdooyinka waxyeellooyinka halista ah waa is barbar dhig. Si kastaba ha ahaatee, dhacdooyinka hypertension ee bukaanada kooxda ramucirumab waxay ahayd 7.6%, marka la barbardhigo 2.6% ee kooxda placebo. Sida laga soo xigtay warbixinnada cilmi-baarista, daawadu ma aysan arkin qaar ka mid ah dhibaatooyinka ay keeneen dawooyinkii hore ee ka hortagga xididdada dhiigga, sida xinjirowga dhiigga oo kordha, dalool calooleedka, iwm.
